TPWA
CRL icon

Twin Peaks Wealth Advisors’s Charles River Laboratories CRL Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.6K Buy
+79
New +$14.6K ﹤0.01% 900
2025
Q3 		– Sell
-45
Closed -$6.87K – 586
2025
Q2 		$6.87K Buy
+45
New +$6K ﹤0.01% 1129

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Twin Peaks Wealth Advisors's CRL Position: Q1 2026 in Review

Twin Peaks Wealth Advisors opened a new position in Charles River Laboratories (CRL) in Q1 2026: 79 shares worth $13.6K. The stake represents ﹤0.01% of the portfolio and ranks #900 among its holdings. This is a return to the name: Twin Peaks Wealth Advisors previously reported a position in CRL as recently as Q2 2025.

Twin Peaks Wealth Advisors first reported a position in CRL in Q2 2025 and has held it in 2 quarters since. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Twin Peaks Wealth Advisors held 79 shares of Charles River Laboratories worth $13.6K as of Q1 2026.
  • Charles River Laboratories was a new Twin Peaks Wealth Advisors position in Q1 2026.
  • Charles River Laboratories made up ﹤0.01% of Twin Peaks Wealth Advisors's portfolio in Q1 2026, its #900 holding.
  • Twin Peaks Wealth Advisors first reported a position in Charles River Laboratories in Q2 2025 and has held it in 2 quarters since.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q1 2026, filed 8 May 2026.